Literature DB >> 312809

Immune function in systemic lupus erythematosus. Impairment of in vitro T-cell proliferation and in vivo antibody response to exogenous antigen.

A B Gottlieb, R G Lahita, N Chiorazzi, H G Kunkel.   

Abstract

Peripheral blood mononuclear cells from 46 systemic lupus erythematosus (SLE) patients showed reduced ability to proliferate in vitro in response to the soluble antigen, tetanus toxoid, as compared with 96 normal controls. Special studies of 27 untreated SLE patients also revealed significantly decreased blastogenic responses to tetanus toxoid. In both the total and untreated SLE populations, decreased mean tetanus antibody titers also were found as compared with the control population. However, the reduction in antibody titer and blastogenic response was not strictly parallel. A limited immunization program was initiated in low-responding volunteers from the SLE and normal populations. Three out of four SLE patients did not develop a significant blastogenic response despite increases in anti-tetanus titers after immunization, whereas all normals showed significant increases in both blastogenic and antibody responses. The accumulated evidence indicated that the unresponsiveness was the result of a defect in T-cell function. Monocyte reactivity was demonstrated to be normal, and no evidence was found for the presence of suppressor cells, inhibition by immune complexes, or increased prostaglandins to explain the defect.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 312809      PMCID: PMC372029          DOI: 10.1172/JCI109388

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  38 in total

1.  APPEARANCE OF ANTICOAGULANT FACTORS AND CERTAIN "AUTOIMMUNE" ANTIBODIES FOLLOWING ANTIGENIC STIMULATION WITH BLOOD GROUP SUBSTANCES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS.

Authors:  S B ZINGALE; J C SANCHEZAVALOS; J A ANDRADA; S G STRINGA; J A MANNI
Journal:  Arthritis Rheum       Date:  1963-10

2.  Systemic lupus erythematosus and normal antibodies.

Authors:  L H MUSCHEL
Journal:  Proc Soc Exp Biol Med       Date:  1961-03

Review 3.  Characterization of human T-cell subpopulations as defined by specific receptors for immunoglobulins.

Authors:  L Moretta; M Ferrarini; M D Cooper
Journal:  Contemp Top Immunobiol       Date:  1978

4.  Prostaglandin-producing suppressor cells in Hodgkin's disease.

Authors:  J S Goodwin; R P Messner; A D Bankhurst; G T Peake; J H Saiki; R C Williams
Journal:  N Engl J Med       Date:  1977-11-03       Impact factor: 91.245

5.  T cell helper defect in patients with chronic lymphocytic leukemia.

Authors:  N Chiorazzi; S M Fu; G Montazeri; H G Kunkel; K Rai; T Gee
Journal:  J Immunol       Date:  1979-03       Impact factor: 5.422

6.  Influenza immunization in systemic lupus eruthematosus. A double-blind trial.

Authors:  G W Williams; A D Steinberg; J L Reinertsen; L W Klassen; J L Decker; R Dolin
Journal:  Ann Intern Med       Date:  1978-06       Impact factor: 25.391

7.  Monocyte-reactive antibodies in patients with systemic lupus erythematosus.

Authors:  W P Arend; T E Emmerich; J C Sturge; G A Starkebaum
Journal:  Arthritis Rheum       Date:  1977-06

8.  Antigen presentation in the murine T-lymphocyte proliferative response. I. Requirement for genetic identity at the major histocompatibility complex.

Authors:  A Yano; R H Schwartz; W E Paul
Journal:  J Exp Med       Date:  1977-09-01       Impact factor: 14.307

9.  Peripheral human T cells sensitized in mixed leukocyte culture synthesize and express Ia-like antigens.

Authors:  R L Evans; T J Faldetta; R E Humphreys; D M Pratt; E J Yunis; S F Schlossman
Journal:  J Exp Med       Date:  1978-11-01       Impact factor: 14.307

10.  Antigen-specific helper factor in man.

Authors:  F B Mudawwar; E J Yunis; R S Geha
Journal:  J Exp Med       Date:  1978-10-01       Impact factor: 14.307

View more
  27 in total

1.  (T,G)-A-L specific immune response potential and HLA typing of Israeli patients with systemic lupus erythematosus.

Authors:  Y Shalev; Z Bentwich; D Katz; C Brautbar; E Mozes
Journal:  Clin Exp Immunol       Date:  1985-05       Impact factor: 4.330

2.  Altered editing in RNA editing adenosine deaminase ADAR2 gene transcripts of systemic lupus erythematosus T lymphocytes.

Authors:  Dama Laxminarayana; Kenneth S O'Rourke; Stefan Maas; Irene Olorenshaw
Journal:  Immunology       Date:  2007-03-22       Impact factor: 7.397

Review 3.  The cytokine network in the pathogenesis of systemic lupus erythematosus and possible therapeutic implications.

Authors:  D A Horwitz; C O Jacob
Journal:  Springer Semin Immunopathol       Date:  1994

4.  Defective in vitro IL-2 production in lupus is an early but secondary event paralleling disease activity: evidence from the murine parent-into-F1 model supports staging of IL-2 defects in human lupus.

Authors:  Charles S Via; Gene M Shearer
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

5.  Cellular immunity to possible synovial antigens in rheumatoid arthritis.

Authors:  A D Robinson; K D Muirden
Journal:  Ann Rheum Dis       Date:  1980-12       Impact factor: 19.103

6.  Defective expression and tyrosine phosphorylation of the T cell receptor zeta chain in peripheral blood T cells from systemic lupus erythematosus patients.

Authors:  M Pang; Y Setoyama; K Tsuzaka; K Yoshimoto; K Amano; T Abe; T Takeuchi
Journal:  Clin Exp Immunol       Date:  2002-07       Impact factor: 4.330

7.  Interleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by Fas ligand.

Authors:  L Georgescu; R K Vakkalanka; K B Elkon; M K Crow
Journal:  J Clin Invest       Date:  1997-11-15       Impact factor: 14.808

8.  Serum deoxyribonuclease I and clinical activity in systemic lupus erythematosus.

Authors:  S Chitrabamrung; R L Rubin; E M Tan
Journal:  Rheumatol Int       Date:  1981       Impact factor: 2.631

9.  Expression of CTLA-4 molecule in peripheral blood T lymphocytes from patients with systemic lupus erythematosus.

Authors:  M F Liu; H S Liu; C R Wang; H Y Lei
Journal:  J Clin Immunol       Date:  1998-11       Impact factor: 8.317

10.  Deficient type I protein kinase A isozyme activity in systemic lupus erythematosus T lymphocytes.

Authors:  G M Kammer; I U Khan; C J Malemud
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.